We present a 76-year-old man who developed papulopustular rosacea after receiving nivolumab treatnnent for his esophageal carcinonna, metastatic to the lungs. Nivolumab is an emerging cancer therapy whose immune-related adverse events are still not fully recognized and likely underreported. The treatment has been reported to cause a myriad of cutaneous immune-related adverse events. However, nivolumab-induced-papulopustular rosacea has been scarcely reported. Thus, this case presents a clinically important finding that physicians should be aware of when seeing patients on nivolumab therapy.
- Nivolumab-induced rosacea
ASJC Scopus subject areas